TheraRadar
← Back
Data updated: Jun 28, 2026

RISING

Generics
CardiovascularNeurologyDermatology

RISING is a generic drug manufacturer focused on Cardiovascular, Neurology, Dermatology.

1958
Since
255
Drugs
-
Trials
4
New Drugs (2yr)
Modality:
4 Small Molecules

RISING's Key Drugs

RISING's core commercial portfolio centers on LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN (COPACKAGED), SUMATRIPTAN AND NAPROXEN SODIUM, spanning Cardiovascular and Neurology — its most strategically important drugs approved in the last 15 years.

LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN (COPACKAGED)
Infectious Disease

Lower Respiratory Tract Infection

Approved 2013
SUMATRIPTAN AND NAPROXEN SODIUM
CNS

Migraine

5-HT1B Approved 2018

RISING's Recent FDA Approvals

RISING secured 4 new FDA approvals for novel drugs (NDA/BLA) in the last two years.

ROCURONIUM BROMIDE NDA
2025-10-24
rocuronium bromide
Routine tracheal intubation
FAMOTIDINE NDA
2025-07-16
famotidine
1 INDICATIONS AND USAGE Famotidine tablets are indicated in adult and pediatric patients 40 kg and greater for the treatment of: • active duodenal ulcer (DU). • active gastric ulcer (GU). • symptomatic nonerosive gastroesophageal reflux disease (GERD). • erosive esophagitis due to GERD, diagnosed by biopsy. Famotidine tablets are indicated in adults for the: • treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). • reduction of the risk of duodenal ulcer recurrence. Famotidine tablets are a histamine-2 (H 2 ) receptor antagonist indicated ( 1 ): In adult and pediatric patients 40 kg and greater for the treatment of: • active duodenal ulcer (DU). • active gastric ulcer. • symptomatic nonerosive gastroesophageal reflux disease (GERD). • erosive esophagitis due to GERD, diagnosed by biopsy. In adults for the: • treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). • reduction of the risk of DU recurrence.
ROCURONIUM BROMIDE NDA
2025-06-09
rocuronium bromide
Routine tracheal intubation
PYRIDOSTIGMINE BROMIDE NDA
2024-10-04
pyridostigmine bromide
INDICATIONS AND USAGE Pyridostigmine Bromide Tablets USP are useful in the treatment of myasthenia gravis.

RISING's Therapeutic Areas

RISING's approved drugs and pipeline span 5 therapeutic areas, led by Cardiovascular and Neurology, across 0 biologic and 4 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Cardiovascular 34%
20 drugs
Neurology 22%
13 drugs
Dermatology 15%
9 drugs
Infectious Disease 15%
9 drugs
Oncology 14%
8 drugs

RISING Pipeline Snapshot

Active clinical trials for RISING across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN (COPACKAGED) leads revenue
  • • 2 key drugs tracked

Trial Catalysts

  • • Cardiovascular pipeline focus
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling